摘要
社区获得性肺炎(CAP)是儿童死亡的主要原因,探讨临床常用可评估肺炎严重程度的生物标志物的应用价值,协助临床制定诊疗决策十分重要。了解常用生物标志物在儿童重症肺炎诊治中的作用及新型生物标志物的应用前景,可帮助临床医师了解微生物学以外的儿童重症肺炎的评价指标。已知生物标记物中CRP、IL-6、和PCT对预测儿童CAP的严重程度有一定价值,但单个指标的变化不足以准确预测CAP的严重程度,临床需联合应用,且应结合临床表现综合评价。
Community-acquired pneumonia( CAP) is the main cause of death in children.It is very important to explore the application value of biomarkers commonly used in clinic to evaluate the severity of pneumonia and to assist clinical decision-making. Understanding the role of common biomarkers in the diagnosis and treatment of severe pneumonia in children and the application prospect of new biomarkers can help clinicians understand the evaluation indexes of severe pneumonia in children other than microbiology Price index. It is known that CRP,IL-6 and PCT in biomarkers have certain value in predicting the severity of CAP in children,but the change of single index is not enough to accurately predict the severity of CAP.They should be applied in combination in clinic,and CAP should be comprehensively evaluated based on clinical manifestations.
作者
邹映雪
张旭冉
ZOU Ying-xue;ZHANG Xu-ran(The Second Respiratory Department&Infection Department of Tianjin Children's Hospital,Tianjin 300074,China)
出处
《中国实用儿科杂志》
CSCD
北大核心
2022年第2期92-96,共5页
Chinese Journal of Practical Pediatrics
关键词
生物标志物
儿童
炎症
肺炎
biomarkers
child
inflammation
pneumonia
